Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

NCT03930771 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT03930771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03930771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Terminated
Start date
May 21, 2019
Completion date
October 1, 2021
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent pituitary adenomas